Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 7Completed 6Terminated 5Recruiting 5Withdrawn 2Unknown 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 14Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma 2Leukemia, Plasma Cell 2Triple Negative Breast Neoplasms 1Smoldering Multiple Myeloma 1Recurrence 1Paraproteinemias 1Neoplasms, Plasma Cell 1Neoplasms 1Immunoglobulin Light-chain Amyloidosis 1Hematologic Diseases 1Hemangioma, Cavernous, Central Nervous System 1Corneal Diseases 1Blood Protein Disorders 1

Interventions

Cyclophosphamide 6fludarabine 5toripalimab 3Etoposide 3Drug Therapy 3zimberelimab 2tislelizumab 2sintilimab 2glumetinib 2cemiplimab 2Vincristine 2Temozolomide 2Platinum 2Paclitaxel 2Injections 2Immunotherapy, Adoptive 2Immune Checkpoint Inhibitors 2Hepatectomy 2Gemcitabine 2Docetaxel 2Carboplatin 2Capecitabine 2Bevacizumab 2venetoclax 1relmacabtagene autoleucel 1pomalidomide 1pirtobrutinib 1osimertinib 1lenvatinib 1irinotecan sucrosofate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Recurrence × daratumumab × Clear all
NCT07623798 2026-06-03

A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3 Not yet recruiting
255 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡